Posts in category Healthcare

Synergy Pharmaceuticals Inc (SGYP) Savvy Leadership Turnover and Upcoming Trulance Approval in IBS-C Have This Bull Confident

H.C. Wainwright’s Ram Selvaraju commends new CEO Troy Hamilton’s strong background in the biotech-verse and roots for Trulance as a long-term winner in the competitive IBS-C playing field.

HTG Molecular Diagnostics Inc (HTGM) Gets a Price Target Jump from This Bull Following Second Consecutive Financial Outclass

Canaccord’s Mark Massaro is impressed that even after recent HTGM share volatility, the healthcare player still delivered an impressive robust fourth quarter turnout for 2017.

OHR Pharmaceutical Inc (OHRP) Loses Bull After Disappointing MAKO Trial Results

Roth Capital’s Yasmeen Rahimi is left bewildered, having banked on the success of OHRP’s wet-AMD asset, but holds out hope to become more positive on the stock down the line.

Teva Pharmaceutical Industries Ltd (ADR) (TEVA) Stock Could Stay Grounded For Now

There’s been much ado about Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA). The generic drug giant …

Omeros Corporation (OMER) Earns Phase 3 Protocol Nod for Kidney Drug; Jason Kolbert Bullish on This ‘Cash Engine’

OMER shares may be seeing a pullback today, but this bull believes the drug maker has a standout product profile in its kidney asset that can save patient lives.

Teva Pharmaceutical Industries Ltd (ADR) (TEVA) Has Tough Choices to Make, But Could See More Cost Cuts and Upside Over Time

Though in the next 12 months, Cantor’s Louise Chen is hesitant to take a gamble on an Israeli biotech giant just at the beginning of a comeback, she likes what she sees in new TEVA CEO Kare Schultz’s strategy.

Investors Underestimating Value of TherapeuticsMD Inc (TXMD) TX-001 Asset, Bets William Tanner

Cantor’s William Tanner explains that while TXMD asset TX-004 has magnetized the Street’s attention in the last half a year, TX-004 boasts a bigger commercial market.

Celgene Corporation (CELG) Discontinuation Impairment Charge from Failed Crohn’s Drug Program Is Ultimately ‘Insignificant’

Cantor’s Mara Goldstein is not shaken by the $411 million pretax charge impacting CELG in 4Q, as the stock barely dipped past 1% upon the GED-0301 program cancellation news.

Show More